US private equity (PE) giant Blackstone is understood to be exploring exit options for Japan-based Ayumi Pharmaceutical Corp, in a deal that could value the specialty pharmaceutical company at at least $1 billion.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
